Depressed in-patients respond differently to imipramine and mirtazapine

Pharmacopsychiatry

Volumn 32, Issue 3, 1999, Pages 87-92

  Bruijn, J A ^a   Moleman, P ^b   Mulder, P G H ^c   Van Den Broek, W W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Moleman Research   (Netherlands)

^c ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; IMIPRAMINE; LORAZEPAM; MIRTAZAPINE;

ADULT; AGED; AGITATION; ALLERGIC REACTION; ANXIETY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELIRIUM; DEPRESSION; DOSE CALCULATION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG RESPONSE; FEMALE; FEVER; GUILT; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MANIA; MELANCHOLIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SLEEP; SYMPTOM; TRANQUILIZING ACTIVITY;

EID: 0032818485     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-979200     Document Type: Article

References (23)

1. 1 Angst J: Severity of depression and benzodiazepine comedication in relationship to efficacy of antidepressants in acute trials: a meta-analysis of moclobemide trials. Hum. Psychopharmacol. 1993; 8: 401-407
2. 2 Bech P, Gram LF, Dein E, Jacobsen O, Vitger TG, Bolwig TG: Quantitative rating of depressed states. Acta Psychiatrica Scand. 1975; 51: 161-170
3. 3 Blackburn TP: 5-HT receptors and anxiolytic drugs. In: Central serotonin receptors and psychotropic drugs, (eds.) C.A. Marsden and D.J. Heal. Blackwell Scientific Publications, Oxford 1992: 175-197
4. 4 Blier P, DeMontigny C: Current advances and trends in the treatment of depression. Trends Pharmacol. Sci. 1994; 15: 220-226
5. 2-selective adrenoceptor antagonist ORG 3770 (mirtazapine, Remeron®) enhances noradrenergic and serotonergic transmission. Hum. Psychopharmacol. 1995; 10: S107-S118
6. 6 Bruijn JA, Moleman P, Mulder PGH, van den Broek WW, van den Hulst AM, van der Mast RC, van de Wefering BJM: A double-blind, fixed plasma level study comparing mirtazapine with imipramine in depressed inpatients. Psychopharmacology 1996; 127: 231-237
7. 7 Burke MJ, Preskorn SH: Short-term treatment of mood disorders with standard antidepressants. In: F.E. Bloom and D.J. Kupfer (eds). Psychopharmacology: the fourth generation of progress. Raven Press, New York 1995: 1053-1065
8. 8 Danish University Antidepressant Group: Citalopram: clinical effect profile in comparison with clomipramine - a controlled multicentre study. Psychopharmacology 1986; 90: 131-138
9. 9 Danish University Antidepressant Group. Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J. Affect. Disord. 1990; 18: 289-299
10. 10 Danish University Antidepressant Group: Moclobemide: a reversible MAO-A-inhibitor showing weaker antidepressant effect than clomipramine in a controlled multicenter study. J. Affect. Disord. 1993; 28: 105-116
11. 11 Haddjeri N, Blier P, Demontigny C: Effect of the alpha-2-adrenoceptor antagonist mirtazapine on the 5-hydroxytryptamine system in the rat brain. J. Pharmacol. Exp. Ther. 1996; 277: 861-871
12. 12 Hamilton M: A rating scale for depression (HRS). J. Neurol. Neurosurg. Psychiatry. 1960; 23: 56-61
13. 13 Monti JM: Involvement of histamine in the control of the waking state. Life Sci. 1993; 53: 1331-1338
14. 14 Perry PJ, Phohl BM, Holstad SG: The relationship between antidepressant response and tricyclic antidepressant plasma concentrations: a retrospective analysis of the literature using logistic regression analysis. Clin. Pharmacokinet. 1987; 13: 381-391
15. 15 Richelson E: Pharmacology of antidepressants in use in the United States. J. Clin. Psychiatry. 1982; 43 (11 Sec 2): 4-11
16. 16 Richou H, Ruimy J, Charbaut JP, Delisle JP, Brunner H, Patris M, Zirkov M: A multicentre, double-blind, clomipramine-controlled efficacy and safety study of Org 3770. Hum. Psychopharmacol. 1995; 10: 263-271
17. 17 Rickels K, Schweizer EE: Pharmacotherapy of anxiety and panic. In: Psychopharmacology: the third generation of progress, (ed.) H.Y. Meltzer. Raven Press, New York 1987: 1193-1203
18. 18 Roehrs T, Claiborue D, Knox M, Roth T: Effects of ethanol, diphenhydramine, and triazolam after a nap. Neuropsychopharmacology 1993; 9: 239-245
19. 19 Ruigt GSF, Kemp B, Groenhout CM, Kamphuisen HAC: Effect of the antidepressant Org 3770 on human sleep. Eur. J. Clin. Pharmacol. 1990; 38: 551-554
20. 20 Song F, Freemantle N, Sheldon TA, House A, Watson P, Long A, Mason J: Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability. Br. Med. J. 1993; 306: 683-687
21. 21 Spitzer RL, Endicott J: Schedule for affective disorders and schizophrenia (SADS). New York 1978/79
22. 22 Tinklenberg JR: Antianxiety medications and the treatment of anxiety. In: Psychopharmacology, (ed.) J.D. Barchas et al. Oxford University Press, New York 1977: 226-241
23. 23 Zivkov M, De Jong G: Org 3770 vs. amitriptyline: a 6-week randomized double-blind multicentre trial in hospitalized depressed patients. Hum. Psychopharmacol. 1995; 10: 173-180